From symptomatic relief to restorative medicine: a comprehensive review of diabetic erectile dysfunction

Diabetic erectile dysfunction (DMED) represents one of the most prevalent and debilitating complications in men with diabetes, characterized by a complex multifactorial pathogenesis and often suboptimal response to conventional therapies. This review comprehensively summarizes the current understanding of DMED mechanisms and evaluates the evolving therapeutic landscape. We highlight oxidative stress as a pivotal central hub triggered by hyperglycemia, which orchestrates a cascade of detrimental events. Beyond classical endothelial dysfunction and RhoA/ROCK pathway activation, we discuss emerging pathogenic targets, including the activation of the NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome leading to pyroptosis, ferroptosis-induced smooth muscle loss, and epigenetic dysregulation (e.g., upregulated miR-155). Furthermore, the "gut-penis axis" is explored as a novel link between microbiota dysbiosis and systemic inflammation affecting erectile function. Critically, this review assesses the paradigm shift from symptomatic management to restorative therapies. While phosphodiesterase type 5 inhibitors (PDE5i) remain the first-line treatment, they exhibit a non-response rate of approximately 40-50% in diabetic men due to severe neuropathy and endothelial damage. Consequently, emerging regenerative modalities are gaining prominence. We evaluate the efficacy of low-intensity extracorporeal shockwave therapy (Li-ESWT) in promoting angiogenesis and the strategic transition from stem cell transplantation to cell-free exosome therapies to overcome immunogenicity. Additionally, novel pharmacotherapies such as sodium-glucose cotransporter-2 (SGLT2) inhibitors are discussed for their potential to reduce sympathetic overactivation. Finally, we propose a comprehensive, stepwise clinical management algorithm-ranging from metabolic optimization to regenerative interventions and penile prostheses-to achieve personalized precision medicine for refractory DMED patients.